AR080527A1 - Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2 - Google Patents
Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2Info
- Publication number
- AR080527A1 AR080527A1 ARP110100828A ARP110100828A AR080527A1 AR 080527 A1 AR080527 A1 AR 080527A1 AR P110100828 A ARP110100828 A AR P110100828A AR P110100828 A ARP110100828 A AR P110100828A AR 080527 A1 AR080527 A1 AR 080527A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- postaglandine
- antagonist
- receiver
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a un compuesto de amino-piridina 2,6-sustituida-4-monosustituida de la formula (1) o un enantiomero del mismo, o un profármaco éster o una sal del mismo farmacéuticamente aceptable, o una composicion farmacéutica que comprende un compuesto de este tipo. Incluye también un método de tratamiento de un paciente mediante la administracion de una cantidad farmacéuticamente eficaz de un compuesto de este tipo. util para trastornos alérgicos, asma bronquial, rinitis, dermatitis alérgica, degeneracion macular, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31442110P | 2010-03-16 | 2010-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080527A1 true AR080527A1 (es) | 2012-04-11 |
Family
ID=43991061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100828A AR080527A1 (es) | 2010-03-16 | 2011-03-15 | Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20130005741A1 (es) |
EP (1) | EP2547673A1 (es) |
JP (1) | JP2013522307A (es) |
KR (1) | KR20130008043A (es) |
CN (1) | CN103025726A (es) |
AR (1) | AR080527A1 (es) |
AU (1) | AU2011227420A1 (es) |
BR (1) | BR112012023039A2 (es) |
CA (1) | CA2793324A1 (es) |
MX (1) | MX2012010038A (es) |
RU (1) | RU2012143978A (es) |
SG (1) | SG183531A1 (es) |
TW (1) | TW201204708A (es) |
UY (1) | UY33279A (es) |
WO (1) | WO2011115943A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201318624A (zh) * | 2011-09-29 | 2013-05-16 | Shionogi & Co | 包含pgd2拮抗劑及組織胺拮抗劑之過敏性鼻炎治療用醫藥 |
EP2912458B1 (en) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
US10246462B2 (en) | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
SG11202002065VA (en) | 2017-09-13 | 2020-04-29 | Progenity Inc | Preeclampsia biomarkers and related systems and methods |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0983269A4 (en) | 1997-05-29 | 2001-06-27 | Lilly Co Eli | PROCESSES USEFUL FOR THE PREPARATION OF HETEROCYCLIC COMPOUNDS |
AU4971600A (en) | 1999-05-21 | 2000-12-12 | Eli Lilly And Company | Immunopotentiator agents |
DE60115411D1 (de) | 2000-04-12 | 2006-01-05 | Merck Frosst Canada & Co Kirkl | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
AR060403A1 (es) * | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
-
2011
- 2011-03-15 AU AU2011227420A patent/AU2011227420A1/en not_active Abandoned
- 2011-03-15 AR ARP110100828A patent/AR080527A1/es unknown
- 2011-03-15 KR KR1020127026827A patent/KR20130008043A/ko not_active Application Discontinuation
- 2011-03-15 JP JP2013500143A patent/JP2013522307A/ja not_active Withdrawn
- 2011-03-15 WO PCT/US2011/028433 patent/WO2011115943A1/en active Application Filing
- 2011-03-15 RU RU2012143978/04A patent/RU2012143978A/ru unknown
- 2011-03-15 SG SG2012063897A patent/SG183531A1/en unknown
- 2011-03-15 TW TW100108624A patent/TW201204708A/zh unknown
- 2011-03-15 CN CN2011800243949A patent/CN103025726A/zh active Pending
- 2011-03-15 BR BR112012023039A patent/BR112012023039A2/pt not_active Application Discontinuation
- 2011-03-15 EP EP11710375A patent/EP2547673A1/en not_active Withdrawn
- 2011-03-15 CA CA2793324A patent/CA2793324A1/en not_active Abandoned
- 2011-03-15 MX MX2012010038A patent/MX2012010038A/es not_active Application Discontinuation
- 2011-03-16 UY UY0001033279A patent/UY33279A/es not_active Application Discontinuation
-
2012
- 2012-09-11 US US13/610,005 patent/US20130005741A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112012023039A2 (pt) | 2016-05-17 |
UY33279A (es) | 2011-10-31 |
RU2012143978A (ru) | 2014-04-27 |
AU2011227420A1 (en) | 2012-10-04 |
TW201204708A (en) | 2012-02-01 |
MX2012010038A (es) | 2012-10-01 |
CA2793324A1 (en) | 2011-09-22 |
JP2013522307A (ja) | 2013-06-13 |
KR20130008043A (ko) | 2013-01-21 |
WO2011115943A1 (en) | 2011-09-22 |
SG183531A1 (en) | 2012-10-30 |
CN103025726A (zh) | 2013-04-03 |
EP2547673A1 (en) | 2013-01-23 |
US20130005741A1 (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014001468A2 (pt) | compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a | |
PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
NI201300068A (es) | Moduladores del receptor de glucagón | |
BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
MX347988B (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
MX351305B (es) | Antagonistas del receptor de mineralocorticoides. | |
BR112012016879A2 (pt) | Derivados de fumarato de acido graxo e seus usos | |
BR112013023517A2 (pt) | "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica" | |
BR112015001502A2 (pt) | derivados de tipo azaindazol ou diazaindazol para tratamento de dor | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
UY33278A (es) | Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2 | |
NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
IN2014DN09347A (es) | ||
AR080527A1 (es) | Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2 | |
BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
UY33824A (es) | ?moduladores del receptor del glucagón?. | |
MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. | |
AR083430A1 (es) | Compuestos utiles como agentes terapeuticos para enfermedades, trastornos y condiciones que pueden tratarse inter alia por modulacion de receptores opiaceos, acetilcolinesterasa, receptores de nmda, y recaptacion de serotonina y/o norepinefrina; y composiciones farmaceuticas que comprenden tales compuestos | |
CU20100217A7 (es) | Derivados de quinuclidina como antagonistas de receptores muscarínicos m3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |